CN Patent

CN114751907A — 一种主动靶向叶酸受体近红外荧光分子及其制备方法和用途

Assigned to Nanjing Nuoyuan Medical Devices Co Ltd · Expires 2022-07-15 · 4y expired

What this patent protects

本发明公开了一种主动靶向叶酸受体近红外荧光分子及其制备方法和用途，其结构式如下：其中，M独立地选自H、Na和K。本发明通过利用有机全合成的方法制备了叶酸及其衍生物为主动靶向基团的主动靶向近红外荧光小分子。这种主动靶向近红外荧光分子具有主动靶向性高、特异性强，水溶性好和荧光量子产率高等优点。

USPTO Abstract

本发明公开了一种主动靶向叶酸受体近红外荧光分子及其制备方法和用途，其结构式如下：其中，M独立地选自H、Na和K。本发明通过利用有机全合成的方法制备了叶酸及其衍生物为主动靶向基团的主动靶向近红外荧光小分子。这种主动靶向近红外荧光分子具有主动靶向性高、特异性强，水溶性好和荧光量子产率高等优点。

Drugs covered by this patent

pafolacianine-sodium (PAFOLACIANINE SODIUM)

Patent Metadata

Patent number: CN114751907A
Jurisdiction: CN
Classification: —
Expires: 2022-07-15
Drug substance claim: No
Drug product claim: No
Assignee: Nanjing Nuoyuan Medical Devices Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.